Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder

CONCLUSION: Further trials are warranted to make conclusive recommendations on Atomoxetine for improvement of common clinical symptoms of ADHD in the ASD pediatric population. Given limited approved therapies for common clinical symptoms of ASD in children and adolescents, Atomoxetine could be used as a safe off-label option due to a favorable tolerability profile and minimal adverse effects.

via https://pubmed.ncbi.nlm.nih.gov/41815758/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20260324021007&v=2.19.0.post6+133c1fe